Brainstorm Cell Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Brainstorm Cell Therapeutics wird ein Gewinn- und Umsatzwachstum von 15.9% bzw. 91.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 26.4% pro Jahr wachsen soll.

Wichtige Informationen

15.9%

Wachstumsrate der Gewinne

26.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	91.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	12 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Brainstorm Cell Therapeutics: Upcoming BLA In ALS

Aug 21

BrainStorm Cell Therapeutics Q2 2022 Earnings Preview

Aug 12

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Aug 05

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Mar 22

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Nov 26

Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS

May 30

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?

May 02

Here's Why We're Watching Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Situation

Jan 17

BrainStorm completes dosing in Phase 2 MS Study

Dec 18

BrainStorm launches NurOwn Expanded Access Program

Dec 14

What Percentage Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Do Insiders Own?

Dec 13

BrainStorm's NurOwn flunks in late-stage ALS study

Nov 17

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:BCLI - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-26	-44	N/A	3
12/31/2025	N/A	-25	-13	-12	3
12/31/2024	N/A	-14	-14	-14	3
9/30/2024	N/A	-14	-11	-11	N/A
6/30/2024	N/A	-13	-14	-14	N/A
3/31/2024	N/A	-16	-20	-20	N/A
12/31/2023	N/A	-17	-20	-20	N/A
9/30/2023	N/A	-17	-22	-22	N/A
6/30/2023	N/A	-22	-20	-20	N/A
3/31/2023	N/A	-24	-20	-20	N/A
12/31/2022	N/A	-24	-19	-19	N/A
9/30/2022	N/A	-25	-20	-20	N/A
6/30/2022	N/A	-24	-22	-22	N/A
3/31/2022	N/A	-23	-21	-21	N/A
12/31/2021	N/A	-24	-27	-26	N/A
9/30/2021	N/A	-30	-29	-28	N/A
6/30/2021	N/A	-29	-29	-29	N/A
3/31/2021	N/A	-30	-30	-29	N/A
12/31/2020	N/A	-32	-36	-35	N/A
9/30/2020	N/A	-28	-31	-31	N/A
6/30/2020	N/A	-29	-28	-28	N/A
3/31/2020	N/A	-26	-26	-25	N/A
12/31/2019	N/A	-23	-12	-11	N/A
9/30/2019	N/A	-21	-12	-12	N/A
6/30/2019	N/A	-18	-15	-15	N/A
3/31/2019	N/A	-17	-11	-11	N/A
12/31/2018	N/A	-14	-13	-12	N/A
9/30/2018	N/A	-8	-12	-12	N/A
6/30/2018	N/A	-8	N/A	-1	N/A
3/31/2018	N/A	-5	N/A	-3	N/A
12/31/2017	N/A	-5	N/A	-2	N/A
9/30/2017	N/A	-6	N/A	-1	N/A
6/30/2017	N/A	-5	N/A	-5	N/A
3/31/2017	N/A	-5	N/A	-5	N/A
12/31/2016	N/A	-5	N/A	-6	N/A
9/30/2016	N/A	-6	N/A	-6	N/A
6/30/2016	N/A	-7	N/A	-8	N/A
3/31/2016	N/A	-8	N/A	-8	N/A
12/31/2015	N/A	-8	N/A	-7	N/A
9/30/2015	N/A	-10	N/A	-8	N/A
6/30/2015	N/A	-10	N/A	-7	N/A
3/31/2015	N/A	-9	N/A	-6	N/A
12/31/2014	N/A	-9	N/A	-4	N/A
9/30/2014	N/A	-8	N/A	-4	N/A
6/30/2014	N/A	-6	N/A	-4	N/A
3/31/2014	N/A	-6	N/A	-4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BCLI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: BCLI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: BCLI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: BCLI wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: BCLI wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von BCLI in 3 Jahren voraussichtlich hoch sein wird

Brainstorm Cell Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Price target decreased to US$13.00

Price target increased to US$11.00

No longer forecast to breakeven

Recent updates

Brainstorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Brainstorm Cell Therapeutics Implements 1-for-15 Reverse Stock Split to Meet Nasdaq's Minimum Bid Price Requirement

New major risk - Financial position

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Sep 16, 2024

Brainstorm Cell Therapeutics Receives Deficiency Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Pursuant to Nasdaq Listing Rule 5550(b)(2)

Brainstorm Cell Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $4 million.

Brainstorm Cell Therapeutics Inc. Reaches Alignment with Fda on Cmc Aspects of Phase 3B Nurown®? Clinical Trial

New major risk - Revenue and earnings growth

Brainstorm Cell Therapeutics Announces Appointment of Haro Hartounian as EVP and COO

Brainstorm Cell Therapeutics Inc. Announces Non-Compliance Update

Brainstorm Cell Therapeutics Receives Staff Determination Letter from Nasdaq Regarding it Not Regains Compliance with the Minimum Bid Price Requirement by April 29, 2024 and Submits a Hearing Request to the Nasdaq Hearings Panel to Appeal the Staff’s Determination

Brainstorm Cell Therapeutics Inc. Announces Management Changes

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule

BrainStorm Cell Therapeutics Inc. Announces Agreement with FDA on Special Protocol Assessment for Phase 3b Trial in ALS

New major risk - Shareholder dilution

BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn in ALS

Brainstorm Cell Therapeutics Inc. Announces Executive Changes

BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS

Brainstorm Cell Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance Market Value of Listed Securities Requirement for Continued Listing on The Nasdaq Capital Market

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Dec 18, 2023

Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc

New minor risk - Profitability

BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn for the Treatment of ALS

Brainstorm Cell Therapeutics Inc. to Report Q2, 2023 Results on Aug 14, 2023

BrainStorm Cell Therapeutics Inc. Appoints Bob Dagher as Executive Vice President and Chief Development Officer

Brainstorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair

New minor risk - Market cap size

Forecast to breakeven in 2025

Brainstorm Cell Therapeutics Inc Announces Resignation of David Setboun as Executive Vice President and Chief Operating Officer

Forecast to breakeven in 2025

BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer

Brainstorm Cell Therapeutics Inc. Announces Type A Meeting with FDA Granted for NurOwn®

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Jan 10, 2023

BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug Administration

Brainstorm Cell Therapeutics Seeks FDA Approval of Mesenchymal Stem Cell Therapy Called NurOwn for the Treatment of ALS

Price target decreased to US$13.00

Brainstorm Cell Therapeutics Inc. Receives Refusal to File Letter from FA for Its New Biologics License Application for Nurown for the Treatment of Als

BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium

Brainstorm Cell Therapeutics Inc. Announces Peer Reviewed Publication of Results from the Nurown Phase 2 Progressive MS Trial in Multiple Sclerosis Journal

Brainstorm Cell Therapeutics: Upcoming BLA In ALS

Brainstorm Cell Therapeutics Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for NurOwn for the Treatment of Amyotrophic Lateral Sclerosis

BrainStorm Cell Therapeutics Q2 2022 Earnings Preview

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Brainstorm Cell Therapeutics Inc. Appoints Antal Pearl-Lendner as Chief Legal Counsel

BrainStorm Cell Therapeutics Inc. Announces Presentation of Nurown® Exosome Preclinical Data At ISCT 2022 San Francisco Meeting

Price target increased to US$11.00

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

U.S. Food and Drug Administration Authorizes Further Brainstorm Cell Therapeutics Inc.'s Nurown Dosing Under Expanded Access Program

Brainstorm Cell Therapeutics Announces Peer Reviewed Publication of Nurown's® Phase 3 Study for Als in Muscle and Nerve

BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at the 4th Annual ALS ONE Research Symposium

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

No longer forecast to breakeven

Brainstorm Cell Therapeutics Inc.(NasdaqCM:BCLI) dropped from Russell 3000 Growth Index

Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?

BrainStorm Cell Therapeutics EPS beats by $0.07

New 90-day low: US$4.21

Brainstorm Cell Therapeutics Inc. Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development Program

Who Has Been Buying Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?

Brainstorm Cell Therapeutics Inc. Announces Feedback from FDA Type-C Meeting on Future NurOwn® Manufacturing Plan

BrainStorm Cell Therapeutics EPS misses by $0.18

Brainstorm Cell Therapeutics Inc. to Report Q4, 2020 Results on Feb 04, 2021

BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn® Derived Exosome-Based Treatment for COVID-19 ARDS

Here's Why We're Watching Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Situation

Brainstorm Cell Therapeutics Inc. Announces Completion of All Dosing in NurOwn® Phase 2 MS Study

BrainStorm completes dosing in Phase 2 MS Study

BrainStorm Announces NurOwn® Expanded Access Program